**Bloomwell: Pioneering Germany’s Cannabis Telehealth Revolution**
In the bustling streets of Frankfurt, a small telemedicine company named Bloomwell is making waves in the burgeoning cannabis industry. Established in September 2020, Bloomwell began its journey with a modest two-room doctor’s office and a vision to simplify access to medical marijuana for patients in Germany. Now, just a few years later, Bloomwell is not only a leader in the country’s $900 million cannabis market but is also setting a new standard for how prescription medicines can be delivered.
Back in its early days, Bloomwell faced numerous challenges. Cannabis was still categorized as a narcotic, requiring doctors to write prescriptions on paper and deliver them to pharmacists who had to securely store the product. This wasn’t a simple task, and Bloomwell cleverly employed a team of couriers to facilitate the process, making sure patients received their medication within a week. Co-founder Julian Wiekmann recalls that when they first launched, their website sparked skepticism; many people simply didn’t believe it was real. However, the demand was palpable, and within a month, the company was serving 200 patients a month with just four doctors on board.
Fast forward to today, and Bloomwell has soared to connect over 100,000 patients with 60 qualified doctors. Utilizing proprietary software, the company streamlined the process to send prescriptions electronically, drastically reducing delivery times to just 24 to 48 hours. It’s estimated that Bloomwell’s annual revenue hovers around $55 million, with an impressive profit margin of 30%. The company’s growth trajectory has been nothing short of phenomenal, with prescriptions skyrocketing by 3,300 percent between 2024 and 2025. By December alone, Bloomwell distributed nearly two tons of cannabis—a quantity expected to surge to between 25 and 30 tons in 2026.
As the largest legal marijuana market in the EU, Germany saw cannabis sales nearly double from $500 million in 2024 to about $944 million last year. Bloomwell played a crucial role in this remarkable expansion, operating similarly to popular telehealth platforms in the U.S. Patients fill out online questionnaires that doctors review, after which prescriptions can be issued electronically. If further consultation is needed, Bloomwell arranges video calls, ensuring every patient receives personalized care. Gone are the days of cumbersome paper trails—now it’s as easy as shopping on Amazon!
Bloomwell generates revenue not just from medical cannabis sales, but also from selling software and data to various stakeholders in the healthcare ecosystem. Doctors use this data to manage patient information and payments, while pharmacists keep track of their inventory efficiently. Additionally, Bloomwell cross-sells various products, such as vape devices and documentation for traveling with medical marijuana throughout the EU. Their wholesale venture, Iliosante, contributes around 10% of Bloomwell’s revenue.
The company’s innovative journey began when co-founders Cooper Annis, Julie Wiekmann, and Samuel Mangetsu turned a $50,000 initial investment into a business worth an estimated $250 million today. Although currently operating exclusively in Germany, the potential for expansion is vast; one million people already benefit from medical cannabis prescriptions, but estimates suggest that up to 20 million could eventually be eligible. Investors believe that Bloomwell is not just a key player in Germany but will also pave the way for the global cannabis movement.
In essence, Bloomwell isn’t just about cannabis; it embodies the future of telehealth in the pharmaceutical space. With their robust network connecting patients, doctors, and pharmacies, they are poised for exceptional growth. There’s something invigorating about a company that tackles challenges with innovative solutions, all while fueling the expansion of the cannabis market. So here’s to Bloomwell—making medicine easier, faster, and more convenient, one prescription at a time!
